{"id":13709,"date":"2024-05-30T05:32:12","date_gmt":"2024-05-30T05:32:12","guid":{"rendered":"https:\/\/expresorgv.online\/home\/?p=13709"},"modified":"2024-05-30T05:32:13","modified_gmt":"2024-05-30T05:32:13","slug":"autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio","status":"publish","type":"post","link":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/","title":{"rendered":"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio"},"content":{"rendered":"\n<p>La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (<strong>Cofepris<\/strong>) inform\u00f3 este mi\u00e9rcoles que autoriz\u00f3 un <strong>ensayo cl\u00ednico<\/strong> destinado a evaluar eficacia, inmunogenia y seguridad de una vacuna contra el virus sincicial respiratorio (VSR) en lactantes y ni\u00f1os peque\u00f1os<\/p>\n\n\n\n<p>El VSR es una de las principales causas de infecciones respiratorias en todo el mundo, y <strong>es particularmente peligroso en poblaciones vulnerables<\/strong>. La aprobaci\u00f3n de este estudio contribuir\u00e1 a ampliar las opciones para prevenir complicaciones graves y muertes asociadas a este virus en poblaci\u00f3n infantil, inform\u00f3 la Cofepris en un comunicado.<\/p>\n\n\n\n<p>El ensayo cl\u00ednico autorizado para esta vacuna es un estudio fase III, que implica <strong>la administraci\u00f3n del biol\u00f3gico a un amplio grupo de pacientes<\/strong> con el objetivo de determinar su uso preventivo y detectar posibles efectos adversos, interacciones y factores externos que puedan alterar su efecto farmacol\u00f3gico.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/i0.wp.com\/editorial.aristeguinoticias.com\/wp-content\/uploads\/2024\/05\/WhatsApp_Image_2024-05-29_at_15.06.23.jpeg?ssl=1\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/editorial.aristeguinoticias.com\/wp-content\/uploads\/2024\/05\/WhatsApp_Image_2024-05-29_at_15.06.23-700x530.jpeg?resize=640%2C485&#038;ssl=1\" alt=\"\" data-recalc-dims=\"1\" \/><\/a><\/figure>\n\n\n\n<p>Este ensayo cl\u00ednico forma parte de los 11 que Cofepris autoriz\u00f3 en los \u00faltimos 15 d\u00edas, como se detalla en el informe quincenal de ampliaci\u00f3n terap\u00e9utica.<\/p>\n\n\n\n<p>Dentro de los insumos para la salud reci\u00e9n registrados se encuentran <strong>11 f\u00e1rmacos y 155 dispositivos m\u00e9dicos<\/strong>, de los cuales 61 se dise\u00f1aron espec\u00edficamente para atenci\u00f3n m\u00e9dica. Se incluyen pr\u00f3tesis vasculares textiles, stents coronarios liberadores de sirolimus, pr\u00f3tesis vasculares, sistemas de fusi\u00f3n intervertebral y pr\u00f3tesis de cadera.<\/p>\n\n\n\n<p>Adem\u00e1s, <strong>se aprobaron 42 dispositivos para diagn\u00f3stico, detecci\u00f3n o medici\u00f3n de enfermedades<\/strong> como hepatitis B, malaria, SARS-CoV-2, influenza y chikungunya. Tambi\u00e9n se expidieron registros para 52 equipos, como hojas para sierra quir\u00fargica, videoscopios, sondas de ultrasonido \u00f3ptico, vaporizadores para anestesia y resucitadores pulmonares, entre otros.<\/p>\n\n\n\n<p>Cofepris <strong>autoriz\u00f3 todos estos insumos<\/strong> para la salud tras haber demostrado, a trav\u00e9s de exhaustivos procesos de evaluaci\u00f3n, que cumplen los m\u00e1s altos est\u00e1ndares de seguridad, calidad y eficacia, afirma el \u00f3rgano regulador.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) inform\u00f3 este mi\u00e9rcoles que autoriz\u00f3 un ensayo cl\u00ednico destinado a evaluar eficacia, inmunogenia y seguridad de una vacuna contra el virus sincicial respiratorio (VSR) en lactantes y ni\u00f1os peque\u00f1os El VSR es una de las principales causas de infecciones respiratorias en todo el mundo, y [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":13700,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-13709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nacional"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio\" \/>\n<meta property=\"og:description\" content=\"La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) inform\u00f3 este mi\u00e9rcoles que autoriz\u00f3 un ensayo cl\u00ednico destinado a evaluar eficacia, inmunogenia y seguridad de una vacuna contra el virus sincicial respiratorio (VSR) en lactantes y ni\u00f1os peque\u00f1os El VSR es una de las principales causas de infecciones respiratorias en todo el mundo, y [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-30T05:32:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-30T05:32:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png\" \/>\n\t<meta property=\"og:image:width\" content=\"675\" \/>\n\t<meta property=\"og:image:height\" content=\"375\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"expreso\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"expreso\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/\"},\"author\":{\"name\":\"expreso\",\"@id\":\"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2\"},\"headline\":\"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio\",\"datePublished\":\"2024-05-30T05:32:12+00:00\",\"dateModified\":\"2024-05-30T05:32:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/\"},\"wordCount\":330,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1\",\"articleSection\":[\"NACIONAL\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/\",\"url\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/\",\"name\":\"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio -\",\"isPartOf\":{\"@id\":\"https:\/\/expresorgv.online\/home\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1\",\"datePublished\":\"2024-05-30T05:32:12+00:00\",\"dateModified\":\"2024-05-30T05:32:13+00:00\",\"author\":{\"@id\":\"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2\"},\"breadcrumb\":{\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage\",\"url\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1\",\"width\":675,\"height\":375},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/expresorgv.online\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/expresorgv.online\/home\/#website\",\"url\":\"https:\/\/expresorgv.online\/home\/\",\"name\":\"\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/expresorgv.online\/home\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2\",\"name\":\"expreso\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g\",\"caption\":\"expreso\"},\"url\":\"https:\/\/expresorgv.online\/home\/blog\/author\/expreso\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/","og_locale":"es_ES","og_type":"article","og_title":"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio","og_description":"La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) inform\u00f3 este mi\u00e9rcoles que autoriz\u00f3 un ensayo cl\u00ednico destinado a evaluar eficacia, inmunogenia y seguridad de una vacuna contra el virus sincicial respiratorio (VSR) en lactantes y ni\u00f1os peque\u00f1os El VSR es una de las principales causas de infecciones respiratorias en todo el mundo, y [&hellip;]","og_url":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/","article_published_time":"2024-05-30T05:32:12+00:00","article_modified_time":"2024-05-30T05:32:13+00:00","og_image":[{"width":675,"height":375,"url":"https:\/\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png","type":"image\/png"}],"author":"expreso","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"expreso","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#article","isPartOf":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/"},"author":{"name":"expreso","@id":"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2"},"headline":"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio","datePublished":"2024-05-30T05:32:12+00:00","dateModified":"2024-05-30T05:32:13+00:00","mainEntityOfPage":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/"},"wordCount":330,"commentCount":0,"image":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1","articleSection":["NACIONAL"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/","url":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/","name":"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio -","isPartOf":{"@id":"https:\/\/expresorgv.online\/home\/#website"},"primaryImageOfPage":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage"},"image":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1","datePublished":"2024-05-30T05:32:12+00:00","dateModified":"2024-05-30T05:32:13+00:00","author":{"@id":"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2"},"breadcrumb":{"@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#primaryimage","url":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1","contentUrl":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1","width":675,"height":375},{"@type":"BreadcrumbList","@id":"https:\/\/expresorgv.online\/home\/blog\/2024\/05\/30\/autoriza-cofepris-innovador-ensayo-clinico-para-vacuna-contra-virus-sincicial-respiratorio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/expresorgv.online\/home\/"},{"@type":"ListItem","position":2,"name":"Autoriza Cofepris innovador ensayo cl\u00ednico para vacuna contra virus sincicial respiratorio"}]},{"@type":"WebSite","@id":"https:\/\/expresorgv.online\/home\/#website","url":"https:\/\/expresorgv.online\/home\/","name":"","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/expresorgv.online\/home\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/expresorgv.online\/home\/#\/schema\/person\/ae1ed1a575540204b5f59dca7f91f6a2","name":"expreso","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/88cd9f065dcd1b722cd984aac4181386a800c0bca699eaf07e42dd8f820bddee?s=96&d=mm&r=g","caption":"expreso"},"url":"https:\/\/expresorgv.online\/home\/blog\/author\/expreso\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/expresorgv.online\/home\/wp-content\/uploads\/2024\/05\/300524CofeprisVacuna.png?fit=675%2C375&ssl=1","_links":{"self":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts\/13709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/comments?post=13709"}],"version-history":[{"count":1,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts\/13709\/revisions"}],"predecessor-version":[{"id":13710,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/posts\/13709\/revisions\/13710"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/media\/13700"}],"wp:attachment":[{"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/media?parent=13709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/categories?post=13709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/expresorgv.online\/home\/wp-json\/wp\/v2\/tags?post=13709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}